0001193125-24-158320.txt : 20240610 0001193125-24-158320.hdr.sgml : 20240610 20240610160553 ACCESSION NUMBER: 0001193125-24-158320 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240604 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vor Biopharma Inc. CENTRAL INDEX KEY: 0001817229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39979 FILM NUMBER: 241032690 BUSINESS ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-655-6580 MAIL ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 8-K 1 d847248d8k.htm 8-K 8-K
false 0001817229 0001817229 2024-06-04 2024-06-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2024

 

 

Vor Biopharma Inc.

(Exact name of registrant as specified in its Charter)

 

 

 

Delaware   001-39979   81-1591163

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

100 Cambridgepark Drive  

Suite 101

Cambridge, Massachusetts

   02140
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 655-6580

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   VOR   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

On June 4, 2024, Nathan Jorgensen, Ph.D., M.B.A., notified Vor Biopharma Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective as of June 21, 2024 (the “Effective Date”), in order to pursue a new opportunity. Dr. Jorgensen’s resignation is not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

The Company is currently conducting a search process to identify a new Chief Financial Officer.

Appointment of Interim Principal Financial Officer and Interim Principal Accounting Officer

On June 8, 2024, the Board designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s interim principal financial officer and Amy Quinlan, the Company’s Vice President of Finance, as the Company’s interim principal accounting officer, effective as of the Effective Date.

Information regarding Dr. Ang’s background and business experience is set forth under the caption “Class III Nominees for Election for a Three-Year Term Expiring at the 2027 Annual Meeting” in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 9, 2024 and is incorporated herein by reference. There are no arrangements or understandings between Dr. Ang and any other persons pursuant to which he was selected as an officer or director of the Company. There are also no family relationships between Dr. Ang and any director or executive officer of the Company, and Dr. Ang has no direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company did not enter into, or materially amend, any material plan, contract or arrangement to which Dr. Ang is a party or in which he participates in connection with Dr. Ang’s designation as interim principal financial officer, or make or modify any grant or award to Dr. Ang under any such plan, contract or arrangement.

Ms. Quinlan, age 49, has served as the Company’s Vice President of Finance since September 2020. Prior to that, Ms. Quinlan served as Vice President, Controller at TetraPhase Pharmaceuticals Inc. from 2008 to August 2020. Ms. Quinlan received her Bachelor of Science degree from Bryant University. There are no arrangements or understandings between Ms. Quinlan and any other persons pursuant to which she was selected as an officer of the Company. There are also no family relationships between Ms. Quinlan and any director or executive officer of the Company, and Ms. Quinlan has no direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company did not enter into, or materially amend, any material plan, contract or arrangement to which Ms. Quinlan is a party or in which she participates in connection with Ms. Quinlan’s designation as interim principal accounting officer, or make or modify any grant or award to Ms. Quinlan under any such plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Vor Biopharma Inc.
Date: June 10, 2024     By:  

/s/ Robert Ang

      Robert Ang
      Chief Executive Officer
 EX-101.SCH 2 vor-20240604.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 vor-20240604_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 vor-20240604_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 04, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001817229
Document Type 8-K
Document Period End Date Jun. 04, 2024
Entity Registrant Name Vor Biopharma Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39979
Entity Tax Identification Number 81-1591163
Entity Address, Address Line One 100 Cambridgepark Drive
Entity Address, Address Line Two Suite 101
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code (617)
Local Phone Number 655-6580
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol VOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d847248d8k.htm vor-20240604.xsd vor-20240604_lab.xml vor-20240604_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d847248d8k.htm": { "nsprefix": "vor", "nsuri": "http://vorbiopharma.com/20240604", "dts": { "inline": { "local": [ "d847248d8k.htm" ] }, "schema": { "local": [ "vor-20240604.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "vor-20240604_lab.xml" ] }, "presentationLink": { "local": [ "vor-20240604_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-04_to_2024-06-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d847248d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-04_to_2024-06-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d847248d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vorbiopharma.com//20240604/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001193125-24-158320-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-158320-xbrl.zip M4$L#!!0 ( +J REAUM$I)2!$ !MG . 9#@T-S(T.&0X:RYH=&WM M7>MSVLBR_^Z_8HJ]>]:I,B!A\ ,[G,*89-G$CPO>/7OOEZU!&F J0J.=D0S< MO_YVSTA"O PV8"?G.%4)",VCIQ^_[IYI*9?_' \]\LBDXL+_^(M=L'XAS'>$ MR_W^QU_JG4:K]7@Q":05-?55W&/^8&81A4B\5Q5WH%Q9Q"7SP6X4:Q M9)6.6C%)'>2?F./^]]FNHV.=2?[_/R\J.\F31=:IA.4+.NXB+>[5+&D^:.0:6OX MWN4B&% YI 5'#)'TLG5BE5,R%%]&! QL%_^\^=IQ!FQ(\]Q7(?6==(HHE"L) M.B_"W:0A5Z)?-BV&DOJJ)X # M(6@+CE3)6Z5\Z20S2!ZT86:@1#O6C7.6/[937L+D_*FESG$1[[IS6ADW/BF: MFW'3U7J"&IY#36?4A8^0AQZKG>6_7!;-UX/+(0LIP>YY]G?$'S_F&L(/F1_F M'T S<\0Q5Q]S(1N'13U<$7H5S8"$D,NN<">U2Y<_$A5.//8QYW(5>'2"JL]R M-7+)QU5LS63\G;LN\\UW:')K])[X=(A]&:_6A\QWX6_XR:/]F()QV&8]N!U) MS=V_4$_SUDG>*O\5BLQ5CG#W8XZ/'_.EDI6K]:BGV&5Q9J:%F;''KYJHOV#Z MOYH^L&;2@/DE]5J^R\9?V"27H6]%@^?16;/ A,[LTU+I?)&^XAR;).LQ"0#& M%%RC/5>5-CR8:Y]PH6="@/J84WP8>.EO XF+!/#()WA1&"LWN4NE(P4JPOHY MBO%B9Q:HKY6(I+G49E.-N:N%M0%WDVY,RRJ]Y"[^T.-,$LU!MM2H&ZTOL_*9 M[XQ4+QT_ $*-[T$>Y;A-0U9;4I;TG-Z;TJKNZ)M=-IVG.,.=E)M3[A6S MUE<$*X6/C*UBKSSU>-^O.K 6)G.S]T?<#0?5LT*%^Q>9MA[KA1=#*OOND$!Z\HL= MC(D2'G?)3Y;^DZO]XR?[Q+JX+ :K)CI>/U'IQ1-EABW#(&1Q :0'HLDK_G^L M:I^EUSTZY-ZD^L"'3)%;-B)M,:3^A;XW,G1WA>=>+!'/[[>MA^8UZ3S4'YJ= MU>18KT1.I]GXO=UZ:#4[I'Y[39I_-GZMWWYNDL;=S4VKTVG=W6Y%8VD7-/ZK MWOFU=?OYX>[VB%P7&@52LBKE\SFZII.>;Z"8L_JPSJ"6*N;)BQ2S8$&S6=V\ M,$9:LG]>7/R&1CI=3((1R^1U_DHZ]>FN?;,Z/+@63H31028^>4%T &&9B8-F M?>^[4NQ!*79BQ S[>;M VDW[^_:#V\/*O>15!'U0Q(*TF$.ZAVQCXF0Q*X< MNA_>GD#1(^& (6V1Y"&'_LVQ,Z!^GY&Z$Q*X;9\?EU?3^5J"Q<@&J6FS0,B0 M'";7C$)DPU1(V".T)%+?9NZ'ZGIHN-?A4=-$3<_&")/#(4Z$51<&&$+W@4LG M$Z"(^5D,*>5JOT4^(^4C@@.\@\G^P:14WH7.K=0@D]NU69\KS.?#6[BSA9,Y MSM7^ $2X2O982,MW"FO4Y'E08>V"'8?-,05(0#:@YU?OY>J]!5\.+D/:]1AQF.>I@#JX?9FSV9?T<=S1./RS]C2I^] M\S[#0(3$]O..===5S*E MXH^OD!?96SCFTUP-Y$4:=-B5W.VS@,IOY%KRQ[W%>JL2@^];9F^;IS];)4I; MJ,19KM:).$0;MF5OM65AOQTK&O#U3CZ(D;\%(\YSM=0NYAEQM'HS[5PX"=8MZ]@.5[_\N#%Z6\4T[9 MD+:5[++U8R8B:UAY&#,+-_3N)2@=#ZA'FF/F1"' .KGK01#"U(?O.3\]!!D3 M%/*'!9$L"9.>=W:Q$Q2:;A3_XZ>SDGUZH8 -'@L&PF?$UV'W$0'>>Q%&6H2" MUH"Z@LJLA@V$K#JTVU*W2\"]$_OTP[KBI^G$7P4(YQXIWS;-+Q_G:B>52OZD MO-=DO@RME[0GAYN MN/M]YI(.N@[RE:HP/BQ[WX+?QW'U.BV#<&# G&_Z=)4&X(0#R7%7IBO&I,L\ M,4*9X4T4)3G+?R$][J'YA/=,^X@ MNL &DRC&I[F9HYD(QI&$^I/D7@^2-3'"?A@8<-Q_4.10,48^,Y])0/^6#WTC MO5ND2+U0*AAZ/U17ZM')2Q/.G2:4:18YS2P74]BY%'J6K8)I^:Z]N]7>>\D0>;%X7%<%HGN5D-R\((#=6(M/?B0M!@;EG0R' MUF*Q77;SIX^3DX?\(%%4QCL#(CC4:5>9RO[I2Q\:WY)BN9YV97%6F#? +6"JB,MZW#=5^F9+S:J0Q6> IH_^')-#E/;IA=Y6 M2QK#-""3 .O[\33"!,VE;KZT9*QESQ.E@V( />V7&;:PWR.@C*+JXX%.'E%[S2-G^ MQ%]Z(NU>D!8ON!_J[1NXL]@/H9?YBD+S":E+B?:+K=6RY@6R&BY/=@&7BR4K M^GN5AR! !TM"%,@Q/;1M##CKD4\I?L5T'F5J0E#=)RF+TN M]B/Q4ZS70_5Z9-@);DXI+]F& M])G)FVES?$8XH0'='='P@QY$>Q,8SWBC "LN(A_\0H%(_JCJ+4JS92G*\Q-!Q!S3>8 MOV"Z8+#+QN8Q#X.4A],P4&1&K@\GY+\C[GO47T[D'] T0ZE(%(T]8^I,W"D2 M")^''!U@SN#*_NVOY:>OG,-@' 2*)*;X!*),%]6ESC>([B,4!OSM1@IB,[!& M-L98'(]0T((5"S%J!5R:'I$XD+GA! EPX]ZK&;_5:I%;,82!@"R,Y5,GCQ>4 M/ P ZO+_ ^9/'I@<@FX$7&I,"/7(H(RGH&]^!"R^80SY&V,Q(O$RT>@TEVL. M YR,)T270FO[['$/E#C%U$RFBNM-0__IXUD(MW60L6<6A-W4\H>92/Q.LZJC%*L?97YOU([-B,H/YR\XY.ODOA1B< M7]6!NMRDSCI=0*:((^17PB:0&L5W(QXE,4)YLS+8!M2/P"H-!0M3@@TS_FC D5Q19\ \@T = MQ[@3EV&D:X:\DA.4[.\^U^_E#2#Z0'V;G;T;5O;==F:77X-&NNFVP3G0T;+C 3?"C0'<"W'-F9!YJ5N,1:C^ M<$.8MTQUV8!Z/0RX<2#C#4P#1&:P V&& ]D,A(2%N0O^/K/FTIX+GZ[NVM?- M=KYQ]_5K_;[3K"9?MGYP'M3NP%0['2PK*ZR@(1QL7;%4WG"8%?5..R*BDI9- MQ6O>2U$#@ NZIX^YX]P*:O'P>J,BLL7C\O6#/U%>M>9IR&5ODGOJ0=7,\A=* M.I*C'["+^:5F;TW74]IYL]>I75DA.-R87CGEYKL,,Q=6W%U:2Z M)UJ?6>VTYK3NF9ZGJ(J97GKU^=_!''<'9^<04Q+)VK;,;8[>UM4LR%LEK6 MCAALDNN201QW_O]3R&>B3<3=S,A$FP4KG&%N52$CIYB\T(@\ZD%_CMO"4"6\Q:Z!10GW?@_#F&?5&_Y MR.TH -+Q>,R"=4-2X1Y&T+*_ M88TQ>'/GC)C5#L^U*<]PSFM)J%K]7W,IY@*+X$6-6J)R#WP>>CAN%NBN>(FV MXCD^*=743X_%15)3]O7CY>?0:M&I!P"$[A-EI8V#I@DO=1XNQYYT^E]Q5X78 M;\7I,!ZE"9%%H+94[RDAL!<+Z8K[+"'KSCA8B-W5P7X1^\6NTQ_O^V=G8/,^ M^_C'/O[T^*#XM^;!+U"BU=5+Q?2&VO-KHKC(FYG5+ ^ORSWR1;W9306?AS=[ M#]X<(^VIX4RNE';AH+X27E5"S76[19N^B;.NDZWRYL905!>WJOKL$XX#[[T M9O!V>BNY7%/[;IA$EM(N>[?S]T9;&7QJM 2Q--M#T78'_:GG]>38_3G7Y %^ M\65ZL?MU6#\/S/$[K72Y:D2>Z;SV+U#W_4X5'Q1)6UU07Q'8RXI T#LR)?=O M![FO178R"Z2_;B(T;SKP'_IGUS'TEUP5T-!!C^^$;9)L\M<6BW_5:5CG7.:U M7">]!;<>^X";Y3H<>:]L-Z[=[0K676*V>8O;G?YM;[:::4,_?P!02P,$% M @ NH#*6#_Z"UNK!@ I4D !0 !V;W(M,C R-# V,#1?;&%B+GAM;,V< M;V_;-A#&WQ?H=[AY;S:@LF.G&!"C:9$YR1 L;8+&W88-0R%+C$U,(@U2CNUO M/U)_&CFF9"H\57G15)'NGKM'_IW"R%;>?=C$$3P0(2EGI[UA_Z@'A 4\I&Q^ MVEM)SY?P(-%DBSE>#!8K]?] M\)XRR:-5HB1E/^#Q #ROB)],O\ ?6;DQ?"81\26!V)<)$?#KBD;A>'0T.AX> M#4?]43E-$%_K0>@G9 R_#(9' Q7X%H;#\=OC\=L3N/T(%ZD,@RF-23F7+[>" MSA<)_!3\#&G6.6>,1!'9PB5E/@NH'\%=T?(;N&)!'\ZB"#[K-*GZE$0\D+"? MJT:4_3?67V:Z>WC]"D"=1B;3?:<]?3+R<[&9B:C/Q5PU>W0\*%)ZCQF;O93U M<9HP/#DY&:1'R]&2FF*5^'#PU\?KNV!!8M]3IU^]7$%>1M*Q3/=?\R ]AQ8- M0F6$_LXKPCR]RQN.O.-A?R/#WGM=,#\[_HQ$UVH+4@]CP2-24U@?3JOW\OAD MNU3Q9),0%I)<^9LV#_*HA2#WF:J&+Y64).C/^<,@)%03Q,39SV#$F#W89TW)D(=K1\$10Z:O. _SQB$'#U MNBT3+U4LTN\%CXU=Y.6XX>#7:!89V]0DJ2T]WH1Y7^X.>RM<6R M(KDC/.NM\)H@%UQK!)&PS2I 7@+2&J"*. /<8NMED)OW[X;T.0]6>FZFJGM; MDG=S.@+8V#C?/^:"Z[X.$J6%,&AE9S3QVRP3:=DK#H:W1% >7K#P7/T^TY3' M)\D=@VFVPFN",% U"&(SFY4 50-T$31\6VC=R+%U_QB+A<]D3O4BF26?_-B: M:'-NITN%"B.\.L9]H6#2PUTG/%8 70)IE=!&WX9%@G7S&"!?L8"+)1?IK9*[ M1 W.A*_4(F4[X6%#K@](=8JYG4UNG>(^!!;RN#.Q4Q#2BI"7!%T3:4B^@R_# MS#S?',807=*(?%K%,R*:34PYK]/Q,!C@YN/NX#_5PJ5JV: MQ@!UZF^N0K58HOM,"[IJA3LUL+EOE4KAB%X MAA^,D3@+0V5 YO]=4T:&S<;!*-#I*-19X@<"W4>@4A07_US_3;$!NA+<,*QU M3&LV#.@_PTL[Z(]2+0&ORP 7H OAPHYMH YU.Q>(F*>_#]^( M6\$?* L:WM:ITG@)P%<9,U'_)!8-?:-N2_QG-S84.D4UW"%HQ4K=)#3P@S@. MMUPF?O0W73:_QVE6> FC8#9E&H2=2+0Q,*BV- 19)5"E,.];MF>C;@"LO3A^ M!E ;%,1O OQN3E>? #0USO>/.7W^;T\'"=STY[Q6QN$4O\^=S_Y9-NL&HOY0 M;G2[X*SA_?+]O(Z K#3 S<==P#1K(<&9BD.JCG7?L)U^RY V:=H-U#\%31+" M)CR.5RR_'REM::U([@C9>BN\)L@%WAI!)(+S"K!;PIGB%ALOH]RT>S><[WA$ M YI0-O^H5MR"^I$MRZ;,CD"N,<&K(EP0KE)#XO=1'@I]9WC;:KE,;J.^W;"] M%43/!U%8I)^$U$_'B)O[>_N%0YU"1QA;F.*'(EVP/J2*A+HZ%])N2+"?0 ,.B]C#*H-FH=A+QYQ)"JTVQJ,K%RK\]&2H]HI M:63+<7E#@I5:3VV'H]F4)I'U/8[]O*Z6-E4&N/FXT[+&J(6UJ,G%0:E#*N^^ MIFFEWYT538.FW4"="E\_:WZWC6?<>@G^)*DC1,VM<\-!%S@-0DADYLJ023M3 MV4*C921MN\6Y;EYL@H5R2YH\S&#.[?CZ:33"JV,PKJ/[>MC7TJ("SL,,[?5M MO*9:-H_Q_MY%3,1<3"HE.W^&KM\4/AKJ_QU<:VV]%\7RG?1[&_LJ#W_ U!+ P04 M " "Z@,I8@DMZ+-X$ #_+0 % '9O&UL MU9I=C^(V%(;O5]K_X*8WK=00 NRT@X99469FA3H?"-BVZLW*) >PZMB1'0;X M]ST.>$L@S,+LMHJYX,/Q>_SZ/(Z)G5R]7R69:EN!\%RN:S%4R:T MY(L,0^I:)). ^+ZMWQM_)+]OFFN3(7"@&DA"=0:*_+I@/&XWZHUF6 \;M<:N M3 $U\4A,,VB3BR"L!UBQ1<*PW6JV6Y=D\$!N\S""C%D"NUJ9KA6;S3/R0_0C MR54W4@C@'-;DC@DJ(D8Y&5G+/Y&^B&JDRSD9&IE&GQK4,\2U;53.Q-]M\S8Q M[LG;-P1?F$BA\]*.9]*QS<9JHGA-JAG:K3<#*_)V-:L#T;*92\++R\L@/UJL MKUE9;6P@#/Y\N!]%G)B&J#:3ST$,S+38-%],>IIY:O#'IY[$^:([ MT9FB459, 3=#12I;R.D$>,+I[)%5, M*H2-)1Y9:/0B4^.:;;A]UF5O$J5-#7O,;X]F,QA[V0%'>QP&_ M^@W6IV(Z(JXNKB.&+;:F,]CL?#+&-)Y*JZBI+J2B3\OFG7-L!H!><;J/;_"R MZ%Q(>^+JT]HS;+%=.(-M,S<,8<9,1T7V2).3J95KJPNMW*]E]K-CS'!%(%4J M59[:$688>G*!4_RZ)^,S$7XA5-6)?L&^!?R+8X#O&(?'13(!=1[-75W5T>UZ MM9PN'>,TIJM^C&E@4[99E;X&VM$@52=XU/@69[/N&,YN'&.2]?8#5\@0GH>R M-$#5,9::M@A#YQ$VOA9APT6$C7\1NK8VW_:BAU^?U%@NQ:L [LH=P;=KV<)S M9X5>Z$I^*?:D!DH^,[/K^QJ"!S$B^YWE)LN;.'LM>; MOM8+4%_/LB2.,T1+O%NN[FRLC"!:&(MA8S)F&3_Y4O)05UUNAUXM)W=V3\:* MF@?E1NMD(D_^N]L359?0GE&+QYW]$3O$;E?1G(H9G'.[M5Q;75CE?BTSU_9! M;A-0,QQ['Y1<9G.;G' O/<\N:(>3-/X6+)/U!+ 0(4 Q0 ( +J MREAUM$I)2!$ !MG . " 0 !D.#0W,C0X9#AK+FAT M;5!+ 0(4 Q0 ( +J REA8,N4H0@, $H+ 0 " 701 M !V;W(M,C R-# V,#0N>'-D4$L! A0#% @ NH#*6#_Z"UNK!@ I4D M !0 ( !Y!0 '9O&UL4$L! A0# M% @ NH#*6()+>BS>! _RT !0 ( !P1L '9O&UL4$L%!@ $ 0 _@ -$@ $! end XML 16 d847248d8k_htm.xml IDEA: XBRL DOCUMENT 0001817229 2024-06-04 2024-06-04 false 0001817229 8-K 2024-06-04 Vor Biopharma Inc. DE 001-39979 81-1591163 100 Cambridgepark Drive Suite 101 Cambridge MA 02140 (617) 655-6580 false false false false Common Stock, $0.0001 par value per share VOR NASDAQ true false